Engelhardt M, Kortum K, Goldschmidt H, Merz M
Haematologica. 2024; 109(8):2420-2435.
PMID: 38356448
PMC: 11290544.
DOI: 10.3324/haematol.2023.283058.
Nieto M, Hedjar A, Locke M, Caro J, Saif M
J Clin Haematol. 2023; 4(1):35-42.
PMID: 38009096
PMC: 10673627.
DOI: 10.33696/haematology.4.055.
Keller A, Sherbenou D, Forsberg P, Mark T
Front Oncol. 2022; 12:925818.
PMID: 35814431
PMC: 9263699.
DOI: 10.3389/fonc.2022.925818.
Alonso R, Lahuerta J
Front Oncol. 2022; 11:800309.
PMID: 35096603
PMC: 8794792.
DOI: 10.3389/fonc.2021.800309.
Runcie K, Mark T
Curr Hematol Malig Rep. 2015; 10(4):388-94.
PMID: 26275667
DOI: 10.1007/s11899-015-0282-1.
DNA repair mechanisms in cancer development and therapy.
Torgovnick A, Schumacher B
Front Genet. 2015; 6:157.
PMID: 25954303
PMC: 4407582.
DOI: 10.3389/fgene.2015.00157.
Current therapeutic strategies for multiple myeloma.
Torimoto Y, Shindo M, Ikuta K, Kohgo Y
Int J Clin Oncol. 2015; 20(3):423-30.
PMID: 25855312
DOI: 10.1007/s10147-015-0826-3.
Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma.
Isoda A, Kaira K, Iwashina M, Oriuchi N, Tominaga H, Nagamori S
Cancer Sci. 2014; 105(11):1496-502.
PMID: 25220100
PMC: 4462375.
DOI: 10.1111/cas.12529.
CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma.
Murray M, Gavile C, Nair J, Koorella C, Carlson L, Buac D
Blood. 2014; 123(24):3770-9.
PMID: 24782505
PMC: 4055924.
DOI: 10.1182/blood-2013-10-530964.
Advances in treatment for relapses and refractory multiple myeloma.
Richards T, Weber D
Med Oncol. 2010; 27 Suppl 1:S25-42.
PMID: 20213220
DOI: 10.1007/s12032-009-9407-5.
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells.
Obeng E, Carlson L, Gutman D, Harrington Jr W, Lee K, Boise L
Blood. 2006; 107(12):4907-16.
PMID: 16507771
PMC: 1895817.
DOI: 10.1182/blood-2005-08-3531.
Multiple myeloma.
MacLennan I, Drayson M, Dunn J
BMJ. 1994; 308(6935):1033-6.
PMID: 8068084
PMC: 2539886.
DOI: 10.1136/bmj.308.6935.1033.
Effect of renal dysfunction in dogs on the disposition and marrow toxicity of melphalan.
Alberts D, Chen H, Benz D, Mason N
Br J Cancer. 1981; 43(3):330-4.
PMID: 7225283
PMC: 2010602.
DOI: 10.1038/bjc.1981.52.
In vitro degradation of L-phenylalanine mustard (L-PAM).
Evans T, Chang S, Alberts D, Sipes I, Brendel K
Cancer Chemother Pharmacol. 1982; 8(2):175-8.
PMID: 7105381
DOI: 10.1007/BF00255479.
Monoclonal immunoglobulin light chains in urine of patients with lymphoma.
Pierson J, Darley T, Stevenson G, Virji M
Br J Cancer. 1980; 41(5):681-8.
PMID: 6775652
PMC: 2010299.
DOI: 10.1038/bjc.1980.129.
Efficacy of the M-2 protocol in previously untreated patients with advanced multiple myeloma.
Gossinger H, Bettelheim P, Neumann E, Hinterberger W, Korninger K, Niessner H
Blut. 1984; 49(5):383-8.
PMID: 6548652
DOI: 10.1007/BF00319886.
Management of multiple myeloma.
MALPAS J
Br Med J. 1969; 2(5650):163-5.
PMID: 5778941
PMC: 1982932.
DOI: 10.1136/bmj.2.5650.163.
Multiple myeloma. Clinical correlation of immunoglobulin changes with therapy. A report of 23 cases.
Basch C, ROSENBAUM E
Calif Med. 1969; 110(1):1-10.
PMID: 5762463
PMC: 1503420.
Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma.
Salmon S, Smith B
J Clin Invest. 1970; 49(6):1114-21.
PMID: 4987170
PMC: 322579.
DOI: 10.1172/JCI106327.
Myeloma nephropathy.
HANICKI Z, HIRSZEL P, Magdon M, Pajdak W, Szczepkowska W, ZEBRO T
Int Urol Nephrol. 1972; 4(4):397-405.
PMID: 4669649
DOI: 10.1007/BF02108145.
